Ganga Pharmaceuticals (539680) H2 24/25 earnings summary

Executive summary

• Audited financial results for the half and full year ended March 31, 2025, were approved and published, with the statutory auditors issuing an unmodified opinion on the statements.

• The company operates solely in the Ayurveda business segment, so no segmental reporting is required.

Financial highlights

• Revenue from operations for FY25 was ₹263.74 lakhs, down from ₹273.58 lakhs in FY24.

• Net profit for FY25 was ₹7.90 lakhs, up from ₹4.66 lakhs in FY24.

• Total income for FY25 was ₹307.33 lakhs, compared to ₹297.53 lakhs in FY24.

• Earnings per share (basic) for FY25 stood at ₹0.16, up from ₹0.11 in FY24.

Key financial ratios and metrics

• Gross margin improved as expenses decreased to ₹297.86 lakhs in FY25 from ₹291.20 lakhs in FY24.

• Share capital remained at ₹483.65 lakhs; reserves and surplus increased to ₹167.36 lakhs from ₹159.48 lakhs.

• Cash and cash equivalents rose to ₹30.24 lakhs at FY25 end, up from ₹2.98 lakhs at FY24 end.